Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alkermes After Elan: A Slow Start But A Maturing Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

As it continues its transformation into a drug development company, Alkermes says it is meeting its own expectations, but analysts are disappointed, at least in the short term.

You may also be interested in...

Alkermes Moves Beyond EDT Merger; Bullish On Pipeline

Newly-reconfigured Alkermes reported third quarter fiscal 2013 earnings, highlighting how far it’s come since merging with the drug delivery unit of Elan a year ago and the strides it’s made with its pipeline of late.

Alkermes' Top Management Takes Its Transformative Message On The Road

Five commercial products, led by long-acting anti-psychotics, will drive growth through 2015, when the new pipeline will start to contribute, management says.

Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes

Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts